[PFE returns Rituxan/Herceptin rights to Celltrion; PFE’s internal (i.e. non-HSP) programs for these FoBs are more advanced than the Celltrion programs originally partnered with HSP.]
Items are shown in reverse chronological order. This table does not purport to be exhaustive.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.